What happened with QTI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
QT Imaging Holdings, Inc. targets hospitals, cancer centers and imaging centers that need additional breast imaging. Its QT Breast Scanner uses sound to produce three-dimensional images without ionizing radiation or breast compression. The FDA has cleared it for breast imaging, but not as a replacement for screening mammography.
Equipment sales account for nearly all revenue, and the United States supplies almost all of the business. U.S. commercialization relies heavily on NXC, its exclusive reseller, although QT Imaging retains specified direct-selling rights. NXC buys scanners for resale and is generally invoiced when they ship. Its agreement includes minimum orders, but those commitments are conditional, including on QT Imaging’s ability to supply equipment. The company also sells QTI Precision Pathway subscriptions, which provide scanner users with software updates, analytics and workflow tools.
QT Imaging remains at an early commercial stage, with limited adoption and production capacity. CMSC is the exclusive manufacturer of scanners distributed by NXC, making that manufacturing relationship important to deliveries. Sales also depend on healthcare providers adopting the equipment and being able to cover scan and interpretation costs through reimbursement and patient payments; insurance coverage and adequate reimbursement remain uncertain.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
QT Imaging’s results depend heavily on NXC’s scanner purchases and Canon’s manufacturing execution, neither of which this list covers.
GE HealthCare competes for the breast-imaging providers that buy QT Imaging’s breast scanners, selling them Invenia automated breast ultrasound systems. For QT Imaging investors, GE HealthCare’s Invenia sales are the business to watch, rather than its broader medical-device revenue.
GE HealthCare Technologies Inc. earningsGEHC
GE HealthCare's report will show whether breast-imaging providers that buy QT Imaging's scanners are also sustaining demand for GE's Invenia automated breast ultrasound systems.
Focus on GE HealthCare's Invenia sales, not its broader medical-device revenue. Stronger sales would show that breast-imaging providers are buying automated ultrasound systems, supporting the case that QT Imaging's target customer base is willing to invest in this category. Weaker sales would point to more cautious provider purchasing and a tougher demand backdrop for QT Imaging, though GE's sales alone cannot establish demand for QT Imaging's distinct scanner.
QT Imaging Holdings, Inc. earningsThis company
QT Imaging earns most of its revenue from breast-imaging scanners, and this report will show whether selling more is improving the margin left after manufacturing costs.
Read scanner sales alongside gross margin, the share of sales left after manufacturing costs. Sales growth with a recovering margin would show that added volume is improving the economics of each scanner; sales growth with a further margin decline would show that costs are still consuming more of each sale, so volume has not yet proved the model can scale.
